Supernus Pharmaceuticals Inc

Overview

Supernus Pharmaceuticals Inc (Supernus Pharmaceuticals) is a specialty pharmaceutical company that develops and commercializes products for the treatment of central nervous system (CNS) diseases. The company's neurology portfolio consists of Oxtellar XR (oxcarbazepine), an adjunct therapy for the treatment of partial seizures; Trokendi XR (topiramate), an initial monotherapy in patients with partial-onset of primary generalized tonic-clonic seizures associated with Lennox-Gastaut syndrome; Apokyn, and Xadago for Parkinson’s disease and Myobloc for cervical dystonia and sialorrhea in adults. Its major pipeline products include SPN-830, SPN-812, SPN-817 and SPN-820. The company's technology platforms include Microtrol (multi particulate delivery platform), Solutrol (matrix delivery platform) and EnSoTrol (osmotic delivery system). Supernus Pharmaceuticals is headquartered in Rockville, Maryland, the US.
Key Stats
Address
9715 Key West Avenue, ROCKVILLE, Maryland
Headquarters

United States of America

Contact

1 301 8382500

No of Employees

563

Industry

Pharmaceuticals and Healthcare

Ticker Symbol & Exchange​

SUPN [NASD]

Revenue (2020)

$520 m

32.4% (2020 vs 2019)
Net Income (2020)

$127 m

12.3% (2020 vs 2019)
Net Profit Margin

24 %

-15.3% (2020 vs 2019)
Market Cap *

$1,450 m

EPS *

$2.4

  *Note: Ratios based on the share price as of 8-September-2021, in absolute numbers and US$.

Peer Comparison

Key Parameters Supernus Pharmaceuticals IncGlenmark Pharmaceuticals LtdSage Therapeutics IncVanda Pharmaceuticals Inc
Key Information
Headquarters United States of America India United States of America United States of America
Headquarter City ROCKVILLE MUMBAI CAMBRIDGE WASHINGTON
Headquarter State/Province Maryland - Massachusetts WashingtonD.C.
No. of Employees 563 13,390 298 292
Entity Type Public Public Public Public

Products & Services

Supernus is a specialty pharmaceutical company that develops and commercializes products for the treatment of central nervous system diseases. The company's key product portfolio includes:

Products
  • Trokendi XR:
  • Epilepsy
  • Migraine
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
  • Vitae Eget Libero
Brands
  • Supernus
  • XADAGO
  • MYOBLOC
  • Rutrum Elit
  • Rutrum Elit
  • Rutrum Elit
  • Rutrum Elit
  • Rutrum Elit
  • Rutrum Elit
  • Rutrum Elit
Key Financial Charts
Sales Growth
Operating Margin
Net Income Growth
EPS (Earnings per Share)
Debt to Equity Ratio
Return on Assets

Employees

Name Position Board Since Age Biography
Timothy C. Dec Senior Vice President; Chief Financial Officer Senior Management 2021 - Mr. Timothy C. Dec has been the Chief Financial Officer and Senior Vice President of the company since 2021. Prior...
Charles W. Newhall, III Chairman Executive Board 2016 76 Mr. Charles W. Newhall, III has been the Chairman of the company since 2016. Previously, he served as a director...
Stefan K.F. Schwabe, M.D., Ph.D. Chief Medical Officer; Executive Vice President - Research and Development Senior Management 2012 69 Dr. Stefan K.F. Schwabe has been the Executive Vice President of Research and Development and the Chief Medical Officer of...
Padmanabh P. Bhatt, Ph.D. Chief Scientific Officer; Senior Vice President - Intellectual Property Senior Management 2012 63 Dr. Padmanabh P. Bhatt has been the Chief Scientific Officer and the Senior Vice President of Intellectual Property of the...
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.
Non Dignissim Eros Proin vel Convallis 2015 XX In vitae nisi ut tortor rutrum suscipit vel vitae ligula. Mauris sed tellus non augue ultricies ultricies. Aliquam vitae urna congue.

History

Year Event Description
2021 Contracts/Agreements In April, the company secured an FDA approval Qelbree for the treatment of attention-deficit hyperactivity…
2020 Acquisitions/Mergers/Takeovers In June, the company acquired CNS portfolio from US WorldMeds LLC, a pharmaceutical company.
2020 Contracts/Agreements In April, the company and Navitor Pharmaceuticals signed an agreement to co-develop Navitor's NV-5138 for…
2018 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2018 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam
2017 Quis autem vel Ut enim ad minima veniam, quis nostrum exercitationem ullam corporis suscipit laboriosam

Locations


Biscayne Neurotherapeutics Inc

Address

Suite 660, 4770 Biscayne Boulevard, Miami
United States of America

Telephone

1 786 5024220

Website

www.biscayneneuro.com

Deals

Number of Deals
Deal Value (US$ m)

Latest Deals

Announced Date Headline Deal Type Acquirers / Investors / Surviving Entity Issuer / partner / Target
19 Apr 2021 Supernus Pharmaceuticals Enters Packaging Agreement with PCI Pharma Services for Qelbree Contract Service Agreement Supernus Pharmaceuticals Inc PCI Pharma Services
02 Apr 2021 Supernus Pharmaceuticals Enters Manufacturing Agreement with Catalent for Qelbree Contract Service Agreement Supernus Pharmaceuticals Inc Catalent Inc
28 Apr 2020 Supernus Pharma Acquires CNS Portfolio from US WorldMeds Asset Transaction Supernus Pharmaceuticals Inc US WorldMeds LLC
21 Apr 2020 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
31 Dec 2019 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit
20 Nov 2019 Lorem ipsum dolor sit amet, consectetur adipiscing elit Eiusmod Tempor Exercitation cillum velit

Jobs Overview

62

Active Jobs

9

Posted

28

Closed

Job Trends

Latest Jobs

Job title Company Country
SENIOR PROFESSIONAL SALES REPRESENTATIVE - LOUISVILLE, KY Supernus Pharmaceuticals Inc United States
SALES REPRESENTATIVE - LOUISVILLE, KY Supernus Pharmaceuticals Inc United States
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar
Cras Malesuada Dolor nisi Lorem minim amet cillum elit. Cursus Sed Pulvinar